Health
23 Oct 2026
Personalised mRNA vaccine cuts melanoma recurrence risk
A phase‑3 study of the personalised mRNA vaccine Intismeran showed a 42 % reduction in melanoma recurrence when combined with the immunotherapy drug pembrolizumab.
Read moreTopic
#Intismeran
1 story